Cargando…

Novel 6-Aminoquinazolinone Derivatives as Potential Cross GT1-4 HCV NS5B Inhibitors

Chronic hepatitis C virus (HCV) infections are a worldwide medical problem responsible for diverse types of liver diseases. The NS5B polymerase enzyme has become a very interesting target for the development of anti-HCV drugs owing to its fundamental role in viral replication. Here we report the syn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nasr, Tamer, Aboshanab, Ahmed M., Mpekoulis, George, Drakopoulos, Antonios, Vassilaki, Niki, Zoidis, Grigoris, Abouzid, Khaled A. M., Zaghary, Wafaa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782603/ https://www.ncbi.nlm.nih.gov/pubmed/36560772 http://dx.doi.org/10.3390/v14122767

Ejemplares similares

Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors
por: Hamdy, Jehad, et al.
Publicado: (2022)

Novel Lipophilic Hydroxamates Based on Spirocarbocyclic Hydantoin Scaffolds with Potent Antiviral and Trypanocidal Activity
por: Pardali, Vasiliki, et al.
Publicado: (2023)

Symmetric Anti-HCV Agents: Synthesis, Antiviral Properties, and Conformational Aspects of Core Scaffolds
por: Leila, Alaa R. S., et al.
Publicado: (2019)

Synthesis, Structure–Activity Relationship, and Mechanistic Studies of Aminoquinazolinones Displaying Antimycobacterial Activity
por: Akester, Jessica N., et al.
Publicado: (2020)

Studies of the symmetric binding mode of daclatasvir and analogs using a new homology model of HCV NS5A GT-4a
por: Saad, Kholoud A., et al.
Publicado: (2022)

Design and Synthesis of Novel Symmetric Fluorene-2,7-Diamine Derivatives as Potent Hepatitis C Virus Inhibitors
por: Mousa, Mai H. A., et al.
Publicado: (2021)

Synthesis and crystal structures of (E)-N′-(4-chloro-3-nitrobenzylidene)acetohydrazide and (E)-2-(4-chlorobenzylidene)-1-(quinolin-8-yl)hydrazine
por: Nasr, Tamer, et al.
Publicado: (2023)

Optimization of Benzoisothiazole dioxide inhibitory activity of the NS5B polymerase of HCV genotype 4 using ligand-steered homological modeling, reaction-driven scaffold-hopping and Enovo workflow
por: Mahmoud, Amr Hamed, et al.
Publicado: (2011)

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283
por: Demetriou, Victoria L, et al.
Publicado: (2010)

A41 Characterization of NS5 coding region resistance associated substitutions from DAA-naïve GT1 HCV-infected patients in a Portuguese cohort
por: Brandao, R, et al.
Publicado: (2018)

Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors
por: Kaushik-Basu, Neerja, et al.
Publicado: (2008)

Geographic Distribution of HCV-GT3 Subtypes and Naturally Occurring Resistance Associated Substitutions
por: Bagaglio, Sabrina, et al.
Publicado: (2019)

Classification of HCV NS5B Polymerase Inhibitors Using Support Vector Machine
por: Wang, Maolin, et al.
Publicado: (2012)

Discovery of Terpenes as Novel HCV NS5B Polymerase Inhibitors via Molecular Docking
por: Karpiński, Tomasz M., et al.
Publicado: (2023)

Identification of NS2 determinants stimulating intrinsic HCV NS2 protease activity
por: Isken, Olaf, et al.
Publicado: (2022)

The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan
por: Huang, Ying-Chou, et al.
Publicado: (2021)

Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent
por: Kwon, Hyock Joo, et al.
Publicado: (2015)

Synthetic bulky NS4A peptide variants bind to and inhibit HCV NS3 protease
por: El-Araby, Moustafa E., et al.
Publicado: (2020)

Probing of Exosites Leads to Novel Inhibitor Scaffolds of HCV NS3/4A Proteinase
por: Shiryaev, Sergey A., et al.
Publicado: (2012)

Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients
por: Paolucci, Stefania, et al.
Publicado: (2013)

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
por: Gao, Min, et al.
Publicado: (2010)

The cobas(®) HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice
por: Fernández-Caballero, J. A., et al.
Publicado: (2017)

Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals
por: Mushtaq, Saima, et al.
Publicado: (2022)

Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia
por: Aissa Larousse, Jameleddine, et al.
Publicado: (2015)

The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032)
por: Meanwell, Nicholas A., et al.
Publicado: (2018)

Performance of NS3, NS5a AND NS5b Hepatitis C Virus (HCV) Antiviral Resistance Sequencing Assays
por: Nutt, Jamie, et al.
Publicado: (2017)

The Future of HCV Therapy: NS4B as an Antiviral Target
por: Dvory-Sobol, Hadas, et al.
Publicado: (2010)

Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?
por: Janardhan, Sujit V, et al.
Publicado: (2015)

Resistance Patterns Associated with HCV NS5A Inhibitors Provide Limited Insight into Drug Binding
por: Issur, Moheshwarnath, et al.
Publicado: (2014)

Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE‐I Part II)
por: Asselah, Tarik, et al.
Publicado: (2019)

Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function
por: Saalau-Bethell, Susanne M., et al.
Publicado: (2012)

A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2015)

VAPC, an Human Endogenous Inhibitor for Hepatitis C Virus (HCV) Infection, Is Intrinsically Unstructured but Forms a “Fuzzy Complex” with HCV NS5B
por: Goyal, Shaveta, et al.
Publicado: (2012)

Dengue Virus Replication Is Associated with Catecholamine Biosynthesis and Metabolism in Hepatocytes
por: Mpekoulis, George, et al.
Publicado: (2022)

Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C
por: Costantino, Angela, et al.
Publicado: (2015)

First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients
por: Hasanshahi, Zahra, et al.
Publicado: (2021)

Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort
por: Shepherd, Samantha J., et al.
Publicado: (2015)

Molecular docking study of P4-Benzoxaborolesubstituted ligands as inhibitors of HCV NS3/4A protease
por: Wadood, Abdul, et al.
Publicado: (2013)

Induction of Intrahepatic HCV NS4B, NS5A and NS5B-Specific Cellular Immune Responses following Peripheral Immunization
por: Lang Kuhs, Krystle A., et al.
Publicado: (2012)

Correction: A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ffr7vecg3p95bgsehv43r30scr